Metformin use may moderate the effect of DPP-4 inhibitors on cardiovascular outcomes

Diabetes Care

Volumn 40, Issue 12, 2017, Pages 1787-1789

  Crowley, Matthew J ^a,b   Williams, John W ^a,b   Kosinski, Andrzej S ^b   D'Alessio, David A ^b   Buse, John B ^c  

^a DURHAM VA MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; METFORMIN; SAXAGLIPTIN; SITAGLIPTIN;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; DIABETES MELLITUS; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; POPULATION RESEARCH; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; TREND STUDY; DRUG INTERACTION; NON INSULIN DEPENDENT DIABETES MELLITUS; PROPORTIONAL HAZARDS MODEL;

DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG INTERACTIONS; HUMANS; METFORMIN; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME;

EID: 85036644041     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc17-1528     Document Type: Article

References (10)

1. Green JB, Bethel MA, Armstrong PW, et al.; TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373:232-242
2. White WB, Cannon CP, Heller SR, et al.; EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:1327-1335
3. Scirica BM, Bhatt DL, Braunwald E, et al.; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-1326
4. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188
5. Knapp G, Hartung J. Improved tests for a random effects meta-regression with a single covariate. Stat Med 2003;22:2693-2710
6. IntHout J, Ioannidis JP, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol 2014;14:25
7. Wu S, Hopper I, Skiba M, Krum H. Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants. Cardiovasc Ther 2014; 32:147-158
8. American Diabetes Association. Standards of Medical Care in Diabetesd 2017. Diabetes Care 2017;40:S1-S135
9. Kårhus ML, Brønden A, Sonne DP, Vilsbøll T, Knop FK. Evidence connecting old, new and neglected glucose-lowering drugs to bile acidinduced GLP-1 secretion: a review. Diabetes Obes Metab 2017;19:1214-1222
10. Bahne E, Hansen M, Brønden A, Sonne DP, Vilsbøll T, Knop FK. Involvement of glucagonlike peptide-1 in the glucose-lowering effect of metformin. Diabetes Obes Metab 2016;18:955-961